ArticleCMAJ open2014
Dispensed prescriptions for quetiapine and other second-generation antipsychotics in Canada from 2005 to 2012: a descriptive study.
Article in CMAJ open, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05303935 (Effects of Quetiapine on Sleep and Next Day Alertness in People With Obstructive Sleep Apnea), which is not on this map. Cited by 40 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Effects of Quetiapine on Sleep and Next Day Alertness in People With Obstructive Sleep Apnea
Who cites it
40 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Metabolic adverse effects of off-label use of second-generation antipsychotics in the adult population: a systematic review and meta-analysis.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2022Pooled it
- Deprescribing antipsychotics for behavioural and psychological symptoms of dementia and insomnia: Evidence-based clinical practice guideline.Canadian family physician Medecin de famille canadien · 2018Guideline
- Quetiapine modestly improves sleep and breathing but impairs next-day performance in people with obstructive sleep apnea and difficulty maintaining sleep: a randomized controlled trial.Annals of the American Thoracic Society · 2026Trial
- Fenofibrate Protects Against Antipsychotic-Induced Hyperglycemia Through Weight Loss and FGF21 Dependent Mechanisms.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026Article
- Patterns and indications for quetiapine prescribing in Dutch primary care: a retrospective database study.BJGP open · 2025Article
- Protective effects of central leptin on whole-body energy homeostasis upon acute olanzapine exposure.bioRxiv : the preprint server for biology · 2025Article
- Influence of CYP2D6 phenotype on adherence, adverse effects, and attitudes in aripiprazole and risperidone users.Acta neuropsychiatrica · 2025Article
- Changes in Sedative Use in British Columbia, Canada from 2012 to 2021: A Drug Utilization Study.Journal of general internal medicine · 2025Article
- Article
- Consumption of psychotropic drugs in Croatia before and during the COVID-19 pandemic: a 10-year longitudinal study (2012-2021).Social psychiatry and psychiatric epidemiology · 2024Article
- Distribution of quetiapine between serum and whole blood in therapeutic drug-monitoring specimens.Journal of analytical toxicology · 2024Article
- Hepatotoxicity of antipsychotics: an exploratory pharmacoepidemiologic and pharmacodynamic study integrating FAERS data andFrontiers in psychiatry · 2024Article
- Antipsychotic-Induced Weight Gain in Severe Mental Illness: Risk Factors and Special Considerations.Current psychiatry reports · 2023Review
- Controversies regarding lithium-associated weight gain: case-control study of real-world drug safety data.International journal of bipolar disorders · 2023Article
- Adverse events with quetiapine and clarithromycin coprescription: A population-based retrospective cohort study.Health science reports · 2023Article
- Inappropriate quetiapine use at a large academic medical center: frequency of misuse and associated costs of adverse effects.Therapeutic advances in drug safety · 2023Article
- Norbuprenorphine Interferences in Urine Drug Testing LC-MS-MS Confirmation Methods from Quetiapine Metabolites.Journal of analytical toxicology · 2022Article
- Article
- Association of Low-Dose Quetiapine and Diabetes.JAMA network open · 2021Article
- 20-Year Trends in the Pharmacologic Treatment of Bipolar Disorder by Psychiatrists in Outpatient Care Settings.The American journal of psychiatry · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe use of antipsychotic drugs, particularly quetiapine, has increased at an unprecedented rate in the last decade, primarily in relation to nonpsychotic indications. This increased use is concerning because of the high rates of metabolic and extrapyramidal side effects and inadequate monitoring of these complications. The purpose of this study was to measure the use of quetiapine and other second-generation antipsychotics by primary care physicians and psychiatrists and the most common diagnoses associated with quetiapine recommendations.
methodsWe analyzed data on antipsychotic use from the IMS Brogan Canadian CompuScript Database and the Canadian Disease and Treatment Index, with a focus on quetiapine. We looked at the number of dispensed prescriptions for second-generation antipsychotics written by primary care physicians and psychiatrists and the diagnoses associated with recommendations for quetiapine from 2005 to 2012.
resultsBetween 2005 and 2012, there was a 300% increase in dispensed prescriptions for quetiapine ordered by family physicians: from 1.04 million in 2005 to 4.17 million in 2012. In comparison, dispensed prescriptions from family physicians for risperidone increased 37.4%: from 1.39 million in 2005 to 1.91 million in 2012; those for olanzapine increased 37.1%, from 0.97 million in 2005 to 1.33 million in 2012. Dispensed prescriptions for quetiapine ordered by psychiatrists increased 141.6%: from 0.87 million in 2005 to 2.11 million in 2012. The top 4 diagnoses associated with quetiapine in 2012 were mood disorders, psychotic disorders, anxiety disorders and sleep disturbances. A 10-fold increase in quetiapine recommendations for sleep disturbances was seen over the study period, with almost all coming from family physicians.
interpretationThese findings indicate a preferential increase in the use of quetiapine over other antipsychotic drugs and show that most of the increased use is a result of off-label prescribing by family physicians.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.